Andrew R Leavitt

US Patent:

61403687, Oct 31, 2000

Filed:

May 4, 1998

Appl. No.:

9/072484

Inventors:

George L. Kenyon - San Francisco CA
Margaret Stauber - Germantown MD
Karl Maurer - Ross CA
Dolan Eargle - San Francisco CA
Angelika Muscate - Loerrach, DE
Andrew Leavitt - San Francisco CA
Diana C. Roe - Newark CA
Todd J. A. Ewing - San Francisco CA
Allan G. Skillman - San Francisco CA
Edward Arnold - Belle Mead NJ
Irwin D. Kuntz - Greenbrae CA
Malin Young - San Francisco CA

Assignee:

The Regents of the University of California - Oakland CA
Rutgers, The University of New Jersey - New Brunswick NJ

International Classification:

A61K 31175

US Classification:

514593

Abstract:

The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.